Quality investing is a long-term, buy-and-hold strategy that focuses on identifying companies with durable competitive advantages, strong profitability, and the ability to generate consistent cash flows. Rather than hunting for the cheapest stocks, quality investors look for businesses that can compound value over many years, often paying a fair price for that resilience. One way to systematically find such candidates is through a multi-factor screen that filters for proven operational efficiency, solid returns on capital, and low debt levels. A recent run of that screen turned up an interesting name in the specialty pharmaceutical space: Amphastar Pharmaceuticals In (NASDAQ:AMPH).
Business Profile
Amphastar develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products, along with insulin active pharmaceutical ingredients (API). Its product lineup includes well-known items like BAQSIMI (glucagon nasal powder), Primatene MIST, and various hospital-use injectables such as Enoxaparin and Naloxone. The company also supplies recombinant human insulin API and porcine insulin API to the broader injectable insulin market. Most of its finished products are used in hospital or urgent care settings, distributed through group purchasing organizations and drug wholesalers.
Meeting the Quality Criteria
The screening methodology behind this find applies several strict fundamental filters designed to isolate businesses with high-quality characteristics. Amphastar’s reported metrics hit or exceed nearly every threshold, making it a standout candidate for further research.
-
Return on Invested Capital (ROIC, excluding cash, goodwill, and intangibles) above 15%: Amphastar posts a ROIC of 15.12%. This is a core measure for quality investors because it shows how efficiently a company turns its invested capital into profits. A double-digit ROIC suggests the business has a meaningful competitive edge and is not simply relying on leverage or accounting goodwill to generate returns.
-
EBIT growth rate exceeding revenue growth rate: Over the past five years, Amphastar’s EBIT has grown at a compound annual rate of 66.4%, while revenue grew at just 3.0%. This divergence is exactly what quality investors look for—it indicates that the company is becoming more profitable over time, likely benefiting from economies of scale, pricing power, or improving operational efficiency. When profits grow significantly faster than sales, it suggests the business model is strengthening, not just expanding.
-
Debt-to-Free Cash Flow ratio below 5: Amphastar’s ratio stands at 4.60, meaning it could theoretically repay all its debt with free cash flow in under five years. Low debt relative to cash generation reduces financial risk and gives the company more flexibility to reinvest, acquire, or weather downturns—key attributes for a long-term hold.
-
Profit Quality above 75%: With a five-year average Profit Quality of 103.97%, Amphastar converts all of its net income into free cash flow. This is an exceptionally strong reading, indicating that earnings are not just accounting constructs but are backed by real cash. High profit quality reduces the risk of unpleasant surprises and gives management real resources to deploy.
The screen also requires at least 5% revenue growth and 5% EBIT growth over five years. While Amphastar’s revenue growth of 3% does not meet the threshold in the base version, its EBIT growth of 66.4% far exceeds the minimum, and the combination of very high ROIC and strong cash conversion still positions it as a compelling quality candidate. Investors running a stricter version of the screen may wish to examine the revenue trend more closely, but the underlying profitability story remains powerful.
High-Level Fundamental Assessment
A full look at the fundamental report reveals a mixed but encouraging picture. Amphastar scores a 6 out of 10 overall when compared against 193 industry peers in the Pharmaceuticals sector. The standout area is profitability, where the company earns top marks across margins, returns on assets and equity, and overall earnings consistency. Its operating margin of 16.20% and profit margin of 11.00% both rank among the best in its peer group, and each has shown improvement in recent years.
On the valuation side, the stock looks extremely cheap. The trailing P/E ratio of 6.74 is below that of 95% of industry peers and well under the S&P 500 average of 26.52. The forward P/E of 6.37 and Enterprise Value-to-EBITDA ratio also underline a deep value profile. Quality investors typically do not lead with valuation, but finding a company with this level of profitability at such a low multiple offers a potential margin of safety.
The financial health score is adequate but not flawless. The current ratio of 3.85 and quick ratio of 2.82 show strong liquidity, and the company has been reducing its share count and debt-to-assets ratio. However, the Altman-Z score of 2.19 sits in the grey zone, and the debt-to-equity ratio of 0.79 is higher than most peers. These are not deal-breakers for a quality investor, but they warrant monitoring.
Growth is the weakest category. While past EPS growth averaged 38.4% annually, the most recent year saw a 17.7% decline, and analysts expect a slight contraction in EPS going forward. This slowdown may explain the depressed valuation and is the primary reason the company does not score higher overall. Still, for a quality investor focused on durability and cash flow rather than rapid expansion, the current setup may still be attractive.
You can review the full detailed breakdown of these fundamental metrics in the AMPH Fundamental Analysis Report.
Valuation Context and Final Considerations
Quality investing does not ignore price, but it prioritizes the business first. In Amphastar’s case, investors are looking at a company with strong profitability, excellent cash conversion, a reasonable debt load, and a very low valuation relative to its industry. The main caveat is that growth has slowed, and future revenue and earnings expectations are modest. That said, if the company can maintain its margins and continue generating high free cash flow, the current price may offer a rare combination of quality and value.
For those interested in running the same screen to find other candidates, you can explore the full results and adjust the filters via the Quality Stock Screener.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.
Read full article here »
View the Zacks #1 Rank List
Amphastar Pharmaceuticals (NASDAQ:AMPH) Screens as a High-Quality Stock with Deep Value Appeal
Quality investing is a long-term, buy-and-hold strategy that focuses on identifying companies with durable competitive advantages, strong profitability, and the ability to generate consistent cash flows. Rather than hunting for the cheapest stocks, quality investors look for businesses that can compound value over many years, often paying a fair price for that resilience. One way to systematically find such candidates is through a multi-factor screen that filters for proven operational efficiency, solid returns on capital, and low debt levels. A recent run of that screen turned up an interesting name in the specialty pharmaceutical space: Amphastar Pharmaceuticals In (NASDAQ:AMPH).
Business Profile
Amphastar develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products, along with insulin active pharmaceutical ingredients (API). Its product lineup includes well-known items like BAQSIMI (glucagon nasal powder), Primatene MIST, and various hospital-use injectables such as Enoxaparin and Naloxone. The company also supplies recombinant human insulin API and porcine insulin API to the broader injectable insulin market. Most of its finished products are used in hospital or urgent care settings, distributed through group purchasing organizations and drug wholesalers.
Meeting the Quality Criteria
The screening methodology behind this find applies several strict fundamental filters designed to isolate businesses with high-quality characteristics. Amphastar’s reported metrics hit or exceed nearly every threshold, making it a standout candidate for further research.
Return on Invested Capital (ROIC, excluding cash, goodwill, and intangibles) above 15%: Amphastar posts a ROIC of 15.12%. This is a core measure for quality investors because it shows how efficiently a company turns its invested capital into profits. A double-digit ROIC suggests the business has a meaningful competitive edge and is not simply relying on leverage or accounting goodwill to generate returns.
EBIT growth rate exceeding revenue growth rate: Over the past five years, Amphastar’s EBIT has grown at a compound annual rate of 66.4%, while revenue grew at just 3.0%. This divergence is exactly what quality investors look for—it indicates that the company is becoming more profitable over time, likely benefiting from economies of scale, pricing power, or improving operational efficiency. When profits grow significantly faster than sales, it suggests the business model is strengthening, not just expanding.
Debt-to-Free Cash Flow ratio below 5: Amphastar’s ratio stands at 4.60, meaning it could theoretically repay all its debt with free cash flow in under five years. Low debt relative to cash generation reduces financial risk and gives the company more flexibility to reinvest, acquire, or weather downturns—key attributes for a long-term hold.
Profit Quality above 75%: With a five-year average Profit Quality of 103.97%, Amphastar converts all of its net income into free cash flow. This is an exceptionally strong reading, indicating that earnings are not just accounting constructs but are backed by real cash. High profit quality reduces the risk of unpleasant surprises and gives management real resources to deploy.
The screen also requires at least 5% revenue growth and 5% EBIT growth over five years. While Amphastar’s revenue growth of 3% does not meet the threshold in the base version, its EBIT growth of 66.4% far exceeds the minimum, and the combination of very high ROIC and strong cash conversion still positions it as a compelling quality candidate. Investors running a stricter version of the screen may wish to examine the revenue trend more closely, but the underlying profitability story remains powerful.
High-Level Fundamental Assessment
A full look at the fundamental report reveals a mixed but encouraging picture. Amphastar scores a 6 out of 10 overall when compared against 193 industry peers in the Pharmaceuticals sector. The standout area is profitability, where the company earns top marks across margins, returns on assets and equity, and overall earnings consistency. Its operating margin of 16.20% and profit margin of 11.00% both rank among the best in its peer group, and each has shown improvement in recent years.
On the valuation side, the stock looks extremely cheap. The trailing P/E ratio of 6.74 is below that of 95% of industry peers and well under the S&P 500 average of 26.52. The forward P/E of 6.37 and Enterprise Value-to-EBITDA ratio also underline a deep value profile. Quality investors typically do not lead with valuation, but finding a company with this level of profitability at such a low multiple offers a potential margin of safety.
The financial health score is adequate but not flawless. The current ratio of 3.85 and quick ratio of 2.82 show strong liquidity, and the company has been reducing its share count and debt-to-assets ratio. However, the Altman-Z score of 2.19 sits in the grey zone, and the debt-to-equity ratio of 0.79 is higher than most peers. These are not deal-breakers for a quality investor, but they warrant monitoring.
Growth is the weakest category. While past EPS growth averaged 38.4% annually, the most recent year saw a 17.7% decline, and analysts expect a slight contraction in EPS going forward. This slowdown may explain the depressed valuation and is the primary reason the company does not score higher overall. Still, for a quality investor focused on durability and cash flow rather than rapid expansion, the current setup may still be attractive.
You can review the full detailed breakdown of these fundamental metrics in the AMPH Fundamental Analysis Report.
Valuation Context and Final Considerations
Quality investing does not ignore price, but it prioritizes the business first. In Amphastar’s case, investors are looking at a company with strong profitability, excellent cash conversion, a reasonable debt load, and a very low valuation relative to its industry. The main caveat is that growth has slowed, and future revenue and earnings expectations are modest. That said, if the company can maintain its margins and continue generating high free cash flow, the current price may offer a rare combination of quality and value.
For those interested in running the same screen to find other candidates, you can explore the full results and adjust the filters via the Quality Stock Screener.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making any investment decisions.
Read full article here »